Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $17.25.

ENTA has been the subject of a number of research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. HC Wainwright lowered their price target on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Robert W. Baird dropped their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $6.10 on Thursday. The firm has a market cap of $129.28 million, a PE ratio of -1.11 and a beta of 0.49. The firm’s 50 day simple moving average is $9.52 and its 200-day simple moving average is $11.61. Enanta Pharmaceuticals has a one year low of $5.70 and a one year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The firm had revenue of $14.60 million for the quarter, compared to analysts’ expectations of $17.99 million. During the same quarter in the previous year, the business earned ($1.33) earnings per share. The company’s revenue for the quarter was down 22.8% compared to the same quarter last year. Equities research analysts predict that Enanta Pharmaceuticals will post -4.73 EPS for the current fiscal year.

Insider Buying and Selling at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 13.64% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in shares of Enanta Pharmaceuticals by 294.2% during the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 20,478 shares in the last quarter. Geode Capital Management LLC increased its stake in Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after purchasing an additional 14,575 shares in the last quarter. Krensavage Asset Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after buying an additional 246,736 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter worth $360,000. Finally, State Street Corp grew its holdings in shares of Enanta Pharmaceuticals by 6.4% during the third quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock valued at $4,662,000 after buying an additional 27,147 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.